Cargando…
Update on the utility of prognostic biomarkers in ovarian cancer
There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the se...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Medicine Reports Ltd
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924732/ https://www.ncbi.nlm.nih.gov/pubmed/20948749 http://dx.doi.org/10.3410/M1-31 |
| _version_ | 1782185625236013056 |
|---|---|
| author | Markman, Maurie |
| author_facet | Markman, Maurie |
| author_sort | Markman, Maurie |
| collection | PubMed |
| description | There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the serum cancer antigen (CA)-125 level, employed to monitor the course of disease in response to treatment or during periods of observation. |
| format | Text |
| id | pubmed-2924732 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2009 |
| publisher | Medicine Reports Ltd |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-29247322010-10-14 Update on the utility of prognostic biomarkers in ovarian cancer Markman, Maurie F1000 Med Rep Review Article There is considerable interest in the gynecologic cancer community for the development of biomarkers that will be of utility in routine management of women with advanced ovarian cancer. However, at the present time, there remains limited evidence for the usefulness of any such test other than the serum cancer antigen (CA)-125 level, employed to monitor the course of disease in response to treatment or during periods of observation. Medicine Reports Ltd 2009-04-29 /pmc/articles/PMC2924732/ /pubmed/20948749 http://dx.doi.org/10.3410/M1-31 Text en © 2009 Medicine Reports Ltd http://creativecommons.org/licenses/by-nc/3.0/legalcode This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. You may not use this work for commercial purposes |
| spellingShingle | Review Article Markman, Maurie Update on the utility of prognostic biomarkers in ovarian cancer |
| title | Update on the utility of prognostic biomarkers in ovarian cancer |
| title_full | Update on the utility of prognostic biomarkers in ovarian cancer |
| title_fullStr | Update on the utility of prognostic biomarkers in ovarian cancer |
| title_full_unstemmed | Update on the utility of prognostic biomarkers in ovarian cancer |
| title_short | Update on the utility of prognostic biomarkers in ovarian cancer |
| title_sort | update on the utility of prognostic biomarkers in ovarian cancer |
| topic | Review Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2924732/ https://www.ncbi.nlm.nih.gov/pubmed/20948749 http://dx.doi.org/10.3410/M1-31 |
| work_keys_str_mv | AT markmanmaurie updateontheutilityofprognosticbiomarkersinovariancancer |